Publications by authors named "Antonio F Casulli"
Renal impairment (RI) is a severe complication throughout the course of multiple myeloma (MM). Bortezomib has been shown to be highly active in MM patients with RI. We designed this retrospective analysis to investigate the safety and efficacy of bortezomib-based therapy in 117 MM patients with RI, 14 cases required dialysis.
View Article and Find Full Text PDFShort-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.
Michele Cavo Francesco Di Raimondo Elena Zamagni Francesca Patriarca Paola Tacchetti Antonio Francesco Casulli
J Clin Oncol
October 2009
Article Synopsis
- This study looked at how adding thalidomide to a specific cancer treatment called double autologous stem-cell transplantation (ASCT) helped young patients with multiple myeloma.
- They compared two groups of patients: one group that received thalidomide and another group that did not.
- The results showed that patients who got thalidomide had better responses to treatment and lived longer without their cancer getting worse, making thalidomide a helpful addition to their care.